Obesity presents a significant global health challenge that lifestyle interventions alone often cannot adequately address. Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a pharmacological solution for chronic weight management.
How Semaglutide Works
Semaglutide functions by mimicking the GLP-1 hormone, which "increases the insulin level in the body, thereby decreasing blood sugar and slowing down digestion." This mechanism not only improves blood sugar control but also facilitates weight reduction.
Clinical Trial Evidence
The STEP trial series provided robust evidence of semaglutide's effectiveness:
- STEP 1: Participants achieved "an average weight loss of 14.9% compared to 2.4% in the placebo group" over 68 weeks
- STEP 2: Demonstrated dual benefits for obesity and type 2 diabetes, with 9.6% weight loss versus 3.4% for placebo
- STEP 4: An extension study showed sustained results, with participants maintaining "a mean weight loss of 16.9%" after continuing treatment
Safety Profile
The long-term safety data supports semaglutide's viability:
- Cardiovascular benefits documented in the SUSTAIN 6 trial
- Renal function unaffected; kidney health improved through weight loss
- Pancreatitis risk remains relatively low
- Common side effects like nausea are typically short-term
Optimal Results
Maximum benefits occur when semaglutide combines with "healthier lifestyle choices like a healthful diet, regular physical activity and behavioural therapy."